Galmed Pharmaceuticals Ltd (GLMD) - Net Assets
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has net assets worth $15.78 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.63 Million) and total liabilities ($2.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GLMD asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.78 Million |
| % of Total Assets | 84.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | -48.25% |
| 10-Year Change | 42.5% |
| Growth Volatility | 138.81 |
Galmed Pharmaceuticals Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Galmed Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Galmed Pharmaceuticals Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual net assets of Galmed Pharmaceuticals Ltd from 2012 to 2025. For live valuation and market cap data, see market cap of Galmed Pharmaceuticals Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.78 Million | -3.34% |
| 2024-12-31 | $16.33 Million | +17.64% |
| 2023-12-31 | $13.88 Million | +3.40% |
| 2022-12-31 | $13.42 Million | -55.99% |
| 2021-12-31 | $30.50 Million | -30.93% |
| 2020-12-31 | $44.15 Million | -36.79% |
| 2019-12-31 | $69.85 Million | -20.53% |
| 2018-12-31 | $87.89 Million | +456.47% |
| 2017-12-31 | $15.79 Million | +42.62% |
| 2016-12-31 | $11.07 Million | -48.60% |
| 2015-12-31 | $21.55 Million | -31.40% |
| 2014-12-31 | $31.41 Million | +1709.79% |
| 2013-12-31 | $-1.95 Million | +1.41% |
| 2012-12-31 | $-1.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galmed Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20062100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.41 Million | 21.59% |
| Other Comprehensive Income | $-303.00K | -1.92% |
| Other Components | $223.46 Million | 1415.89% |
| Total Equity | $15.78 Million | 100.00% |
Galmed Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Komarkcorp Bhd
KLSE:7017
|
$3.77 Million |
|
Judges Scientific Plc
LSE:JDG
|
$3.77 Million |
|
Indo Pureco Pratama Tbk PT
JK:IPPE
|
$3.77 Million |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
$3.78 Million |
|
AGS Transact Technologies Limited
NSE:AGSTRA
|
$3.77 Million |
|
Cosmo Metals Ltd
AU:CMO
|
$3.76 Million |
|
Invion Ltd
AU:IVX
|
$3.76 Million |
|
Great Atlantic Resources Corp
V:GR
|
$3.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galmed Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,327,000 to 15,782,000, a change of -545,000 (-3.3%).
- Net loss of 10,309,000 reduced equity.
- New share issuances of 9,026,000 increased equity.
- Other comprehensive income increased equity by 113,000.
- Other factors increased equity by 625,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.31 Million | -65.32% |
| Share Issuances | $9.03 Million | +57.19% |
| Other Comprehensive Income | $113.00K | +0.72% |
| Other Changes | $625.00K | +3.96% |
| Total Change | $- | -3.34% |
Book Value vs Market Value Analysis
This analysis compares Galmed Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-5.86 | $0.57 | x |
| 2013-12-31 | $-2.74 | $0.57 | x |
| 2014-12-31 | $45.63 | $0.57 | x |
| 2015-12-31 | $29.11 | $0.57 | x |
| 2016-12-31 | $14.60 | $0.57 | x |
| 2017-12-31 | $18.97 | $0.57 | x |
| 2018-12-31 | $72.69 | $0.57 | x |
| 2019-12-31 | $49.62 | $0.57 | x |
| 2020-12-31 | $31.12 | $0.57 | x |
| 2021-12-31 | $18.60 | $0.57 | x |
| 2022-12-31 | $8.01 | $0.57 | x |
| 2023-12-31 | $60.14 | $0.57 | x |
| 2024-12-31 | $17.54 | $0.57 | x |
| 2025-12-31 | $3.66 | $0.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galmed Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -65.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-65.32%) is below the historical average (-58.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.95 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.29 Million |
| 2014 | -28.98% | 0.00% | 0.00x | 1.05x | $-12.24 Million |
| 2015 | -49.30% | 0.00% | 0.00x | 1.13x | $-12.78 Million |
| 2016 | -153.07% | -3630.19% | 0.03x | 1.49x | $-18.06 Million |
| 2017 | -77.87% | -1133.55% | 0.06x | 1.24x | $-13.88 Million |
| 2018 | -11.21% | -483.61% | 0.02x | 1.03x | $-18.65 Million |
| 2019 | -26.54% | 0.00% | 0.00x | 1.10x | $-25.53 Million |
| 2020 | -62.53% | 0.00% | 0.00x | 1.19x | $-32.03 Million |
| 2021 | -104.76% | 0.00% | 0.00x | 1.20x | $-35.00 Million |
| 2022 | -138.35% | 0.00% | 0.00x | 1.23x | $-19.91 Million |
| 2023 | -49.80% | 0.00% | 0.00x | 1.20x | $-8.30 Million |
| 2024 | -46.04% | 0.00% | 0.00x | 1.13x | $-9.15 Million |
| 2025 | -65.32% | 0.00% | 0.00x | 1.18x | $-11.89 Million |
Industry Comparison
This section compares Galmed Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd (GLMD) | $15.78 Million | 0.00% | 0.18x | $3.77 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes me… Read more